Eva van Ingen
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- RNA modifications and cancer
- RNA Research and Splicing
- RNA regulation and disease
- Circular RNAs in diseases
- Extracellular vesicles in disease
Papers in
-
- RNA modifications and cancer 4
- Circular RNAs in diseases 2
- RNA regulation and disease 2
- RNA Research and Splicing 2
-
- MicroRNA in disease regulation 4
- Cancer-related molecular mechanisms research 4
- Co-authors
- A. Yaël Nossent (9 shared papers)Paul H.A. Quax (7 shared papers)Hendrika A. B. Peters (2 shared papers)Laura Parma (2 shared papers)M. Leontien van der Bent (4 shared papers)Johann Wojta (4 shared papers)Ilze Bot (3 shared papers)Margreet R. de Vries (2 shared papers)
- Journals
- Molecular Therapy — Nucleic Acids (4 papers)Cardiovascular Research (2 papers)Advanced Therapeutics (1 paper)Human Molecular Genetics (1 paper)Circulation Research (1 paper)
- Partner nations
- NetherlandsAustriaGermany
In The Last Decade
Eva van Ingen
11 papers receiving 265 citations
Peers
Comparison fields: 5 of 45
- Cancer Research 152
- Molecular Biology 201
- Biomaterials 20
- Immunology 27
- Molecular Medicine 5
Countries citing papers authored by Eva van Ingen
This map shows the geographic impact of Eva van Ingen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva van Ingen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva van Ingen more than expected).
Fields of papers citing papers by Eva van Ingen
This network shows the impact of papers produced by Eva van Ingen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva van Ingen. The network helps show where Eva van Ingen may publish in the future.
Co-authors
The 25 scholars most cited alongside Eva van Ingen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 52 | |
| 2 | 2018 | 41 | |
| 3 | 2020 | 35 | |
| 4 | 2018 | 32 | |
| 5 | 2022 | 26 | |
| 6 | 2021 | 24 | |
| 7 | 2019 | 19 | |
| 8 | 2021 | 17 | |
| 9 | 2022 | 14 | |
| 10 | 2022 | 5 | |
| 11 | 2024 | 1 |
About Eva van Ingen
Eva van Ingen is a scholar working on Molecular Biology, Cancer Research, Immunology, Surgery and Cellular and Molecular Neuroscience, having authored 11 papers that have together received 266 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (4 papers), RNA modifications and cancer (4 papers), Cancer-related molecular mechanisms research (4 papers), Circular RNAs in diseases (2 papers), Atherosclerosis and Cardiovascular Diseases (2 papers), RNA regulation and disease (2 papers), RNA Research and Splicing (2 papers) and Electrospun Nanofibers in Biomedical Applications (1 paper). The work is most often cited by research in Cancer Research (152 citations), Molecular Biology (201 citations), Biomaterials (20 citations), Immunology (27 citations) and Molecular Medicine (5 citations). Eva van Ingen has collaborated with scholars based in Netherlands, Austria and Germany. Frequent co-authors include A. Yaël Nossent, Paul H.A. Quax, Hendrika A. B. Peters, Laura Parma, M. Leontien van der Bent, Johann Wojta, Ilze Bot, Margreet R. de Vries, Hailiang Mei and Amanda C. Foks. Their work appears in journals such as Molecular Therapy — Nucleic Acids, Cardiovascular Research, Advanced Therapeutics, Human Molecular Genetics and Circulation Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.